Pharmacist

Maximize your CME allowance with MDCalc and get up to a $3,500 bonus gift card of your choice. Earn AMA PRA Category 1 Credits^TM for clinical content on 150+ calculators across multiple medical specialties. Easily earn and redeem CME at the point-of-care, online on our website or mobile app. Over 1 million medical professionals use MDCalc’s 550+ tools daily to support clinical decision making at the bedside.

Stay on top of your game with the StatPearls Pharmacist Unlimited CE programs. Your membership allows you unlimited access to 3,290 activities. These Pub-Med Indexed articles are categorized into 15 specialty areas which lets you better access activities that will make the biggest impact on your practice. One subscription allows access to all the activities, including all state-requirements.

Pricing Options

• 6 Month subscription: All 3,393 CE Activities – $59 per 6 months
• Annual subscription: All 3,393 CE Activities – $79 per 1 year

Target Audience: Neurologists

Target Audience: All Prescribing Practitioners

According to the 2015 National Survey on Drug Use and Health, approximately 3.8 million people (1.4% of those ages 12 or older) reported misusing prescription pain relievers, while another 329,000 people reported using heroin. Within the same year, 52,404 lethal overdoses took place, making drug overdose the leading cause of accidental death within the United States. Stancliff et al estimated that as of 2012, approximately 80% of people dependent on heroin or prescription opioids were not engaged in any treatment and many in treatment do not use the most effective medication-assisted treatments available to them.

Despite recent increased awareness of opioid use disorder (OUD) and efforts to improve access to care, several barriers to treatment still exist, including financial, geographic, regulatory, and social. In 2012, only 2.2% of physicians in the United States obtained waivers to prescribe buprenorphine for the treatment of OUD. Of those who received waivers, 41.6% were psychiatrists. This may be perceived as a potential barrier to OUD treatment as patients are often resistant to referrals to psychiatric and/or addiction clinics given the stigmas commonly surrounding addiction and mental health. Furthermore, physicians with waivers were found to practice primarily in urban settings, leaving a large portion of the rural population without access to buprenorphine treatment.

With all this in mind, education is needed in regards to current and emerging treatment options for OUD available to multiple patient populations. Also, with the deaths due to drug overdoses still elevated, education on how to recognize and reverse an opioid overdose is needed.

This presentation will address the above needs by discussing the science behind opioid use disorder as well as reflect upon current statistics associated with its impact on the United States. During the discussion, opioid overdose risks will be discussed and participants will be able to practice recognizing key symptoms of an overdose situation. Steps of using naloxone will be discussed and connected to how to appropriately seek out treatment for maintenance of opioid use disorder. Finally, new buprenorphine products and the potential role of naltrexone will be applied to this stigmatized population.

Notable disparities are present both with regard to individuals in the healthcare profession as well as in the delivery of healthcare to the patient population. Increasing awareness of the importance of diversity, equity, and inclusion is important for expanding access to high quality healthcare.

This presentation will be designed to introduce the audience to an important national level dialogue on the concepts of diversity, equity, and inclusion. Additionally, this topic will be tailored to understanding how DEI relates to healthcare practice and note specific steps the profession is taking to improve DEI at an organizational level.

Countless patients choose to ingest illicit substances while also utilizing prescription medications, and as healthcare professionals, we are left with barely any education on these substances. More education is needed in order to actually provide tangible life-saving, or at least life-improving, patient education.

Forget polypharmacy, what about poly substance abuse? Every 7 minutes an American dies of a drug overdose, propelling pharmacists to expand our knowledge on illicit substances. We humans have always aimed to experience the amplified effects of natural and synthetic substances that produce euphoria. The line between clinical and criminal utilization of substances if often blurred. In our society today, we have a very “objective” classification of substances based on generally accepted medical use and a respective propensity to become habit forming. However, as one can recall with the substance of ethyl alcohol (i.e., beer, wine, and hard liquor), a substance may never actually chemically change, yet can move across legal classifications of substances. How does that happen? Well, join our discussion on illicit substances to learn how numerous illicit substances have similar, if not the same, mechanisms of action as legal prescription medications readily available today. The time has come (Just Say NOW) to progress from “Just Say No” to “Just Say Know”!

This activity aims to assist healthcare professionals in understanding how cannabis can take its place in the medical world. It discusses medicinal cannabis’ uses, modes of administrations, mechanism of action, common drug interactions, and considerations for special populations.

This 2-hour CE discusses vaccine recommendations, as outlined in the Centers for Disease Control and Prevention’s Immunization Schedule. It presents a comparison of COVID-19 vaccine formulations, updates of authorized and approved vaccines, updates on vaccines to other infectious diseases such as varicella, pneumococcus and hepatitis, and reminders of contraindications and precautions for vaccines covered.